Two cholesterol drugs still taken by millions of americans are the subject of concern for a second time.A new study involving about 360 people, showed zetia failed to shrink buildups in artery walls while a rival drug, niaspan, did so significantly.Doctor Barry Horowitz of West Palm Beach was part of studies bringing both medications to market. He said patients on Zetia shouldn't panic.Dr. Barry Horowitz - Metabolic Research Institute: "The sponsor of the study was aboot pharmaceutical which makes niacin. 2nd, it was a small study." "What I think the study shows is a clear benefit for adding Niaspin to a statin treatment for patients who are at a high risk."Last year, a large study suggested that the combo pill "Vytorin", which combines Zetia with a statin, was no more effective than Zocor alone. That's a statin now available as a cheap generic.
You can send a story to multiple email addresses by separating the email addresses with a semicolon (;)
This station will not store your email address or your recipient's email address or use them in any way.
Send your Questions to ask our health expert, Dr. Soria, by using the form provided below.
